US FDA accepts filing of Roxro's intranasal ketorolac
This article was originally published in Scrip
The US FDAhas accepted Roxro Pharma's NDA for its lead candidate, ROX-888 – an intranasal formulation of the NSAID ketorolac for the management of moderate-to-severe pain without the risk of addiction or the other negative effects of narcotics.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.